Profile data is unavailable for this security.
About the company
Hamlet Pharma AB is a Sweden-based company that develops cancer therapeutics. The Company develops cancer therapeutics based on research into protein complexes that selectively induce cell-death in tumours. HAMLET, which stands for Human Alpha-lactalbumin Made LEthal to Tumours, is a protein-fatty acid complex derived from human milk. The complex induces apoptosis in tumour cells while leaving normal cells unaffected. In laboratory experiments, HAMLET is active against many different types of tumour cells, and uses several mechanisms to trigger cell death. HAMLET is also being evaluated clinically on skin papillomas and on bladder cancers. Alpha1H is a Company’s drug candidate for bladder cancer in ongoing phase I/II clinical trials.
- Revenue in SEK (TTM)0.00
- Net income in SEK-17.20m
- Incorporated--
- Employees4.00
- LocationHamlet Pharma ABKlinikgatan 32LUND 222 42SwedenSWE
- Phone+46 40122500
- Websitehttps://hamletpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vivesto AB | 1.02m | -359.69m | 155.76m | 20.00 | -- | 0.5107 | -- | 153.46 | -0.7154 | -0.7154 | 0.002 | 0.5668 | 0.002 | 2.36 | 0.18 | 56,388.89 | -69.70 | -- | -74.00 | -- | -1,048.77 | -- | -35,437.54 | -- | 6.20 | -- | 0.0252 | -- | -96.12 | -- | -175.55 | -- | -- | -- |
| Bioextrax AB publ | 701.53k | -20.17m | 159.65m | -- | -- | 5.75 | -- | 227.57 | -1.10 | -1.10 | 0.0363 | 1.09 | 0.0359 | -- | 1.71 | -- | -103.28 | -- | -124.18 | -- | -93.29 | -- | -2,875.81 | -- | -- | -- | 0.00 | -- | 43.24 | -- | -77.24 | -- | -- | -- |
| Bactiquant A/S | 19.36m | -22.16m | 164.60m | -- | -- | 7.36 | -- | 8.50 | -0.7607 | -0.7607 | 0.6645 | 0.7306 | 0.5195 | 4.23 | 2.95 | -- | -59.48 | -28.60 | -68.98 | -32.61 | -9.30 | -- | -114.50 | -55.76 | 2.78 | -26.93 | 0.2479 | -- | 48.20 | -- | -4.66 | -- | -- | -- |
| Annexin Pharmaceuticals AB (publ) | 0.00 | -41.38m | 165.10m | 4.00 | -- | 8.24 | -- | -- | -0.2716 | -0.2716 | 0.00 | 0.1238 | 0.00 | -- | -- | -- | -123.07 | -111.82 | -144.39 | -132.67 | -- | -- | -- | -- | -- | -20,689.00 | 0.00 | -- | -- | -- | 21.89 | -- | -- | -- |
| StenoCare A/S | 7.01m | -25.47m | 168.57m | -- | -- | 3.86 | -- | 24.03 | -1.32 | -1.32 | 0.3629 | 2.00 | 0.1075 | -- | 2.48 | -- | -39.03 | -- | -46.47 | -- | -- | -- | -363.13 | -- | 1.16 | -12.94 | 0.1776 | -- | 137.54 | -- | -28.04 | -- | -- | -- |
| Xintela AB | 0.00 | -66.22m | 186.59m | -- | -- | 13.84 | -- | -- | -0.3955 | -0.3955 | 0.00 | 0.0188 | 0.00 | 0.00 | -- | -- | -257.29 | -145.61 | -1,598.87 | -254.80 | -- | -- | -- | -14,755.58 | 1.01 | -16.83 | 0.00 | -- | -- | -- | -11.20 | -- | 54.98 | -- |
| Moberg Pharma AB (publ) | 207.00k | -16.30m | 186.79m | -- | -- | 0.344 | -- | 902.37 | -1.88 | -1.88 | 0.0231 | 53.84 | 0.0004 | -- | 0.0348 | -- | -3.25 | -- | -3.36 | -- | 100.00 | -- | -7,873.43 | -- | -- | -- | 0.0091 | -- | -- | -78.39 | 2.40 | -- | -- | -- |
| Orphazyme A/S | 0.00 | -59.86m | 191.73m | 1.00 | -- | 2.95 | -- | -- | -1.09 | 0.7392 | 0.00 | 1.18 | 0.00 | -- | -- | 0.00 | -33.12 | -66.58 | -89.20 | -85.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 51.19 | -- | -- | -- |
| Hamlet Pharma AB | 0.00 | -17.20m | 201.05m | 4.00 | -- | 8.14 | -- | -- | -0.1569 | -0.1569 | 0.00 | 0.3439 | 0.00 | -- | -- | -- | -63.13 | -88.40 | -84.36 | -115.77 | -- | -- | -- | -- | -- | -226.20 | -- | -- | -- | -- | -122.71 | -- | -- | -- |
| ExpreS2ion Biotech Holding AB | 6.66m | -131.08m | 211.04m | 28.00 | -- | 2.03 | -- | 31.68 | -3.36 | -3.36 | 0.172 | 2.11 | 0.0548 | -- | 5.19 | 222,066.70 | -107.81 | -58.88 | -120.43 | -69.62 | -208.69 | 25.33 | -1,967.53 | -394.75 | -- | -- | 0.0547 | -- | -55.21 | -8.89 | -170.02 | -- | 13.21 | -- |
| Lifecare AS | 21.65m | -17.09m | 228.23m | -- | -- | 4.22 | -- | 10.54 | -0.148 | -0.148 | 0.1878 | 0.4688 | 0.4332 | -- | 30.31 | -- | -34.20 | -41.60 | -39.09 | -47.04 | -- | -- | -78.96 | -147.96 | -- | -- | 0.00 | -- | 1,284.20 | 109.30 | -10.08 | -- | -- | -- |
| Kancera AB | 0.00 | -57.98m | 233.92m | 7.00 | -- | 2.55 | -- | -- | -1.01 | -1.01 | 0.00 | 1.12 | 0.00 | -- | -- | -- | -50.93 | -56.25 | -57.99 | -68.43 | -- | 94.68 | -- | -6,023.47 | -- | -78.97 | 0.00 | -- | -- | -- | -14.88 | -- | -- | -- |
| Abliva AB | 31.00k | -79.33m | 238.72m | 6.00 | -- | 1.60 | -- | 7,700.76 | -0.1162 | -0.1162 | 0.00004 | 0.1411 | 0.0003 | -- | 0.001 | 5,166.67 | -72.67 | -73.09 | -81.76 | -85.88 | -- | -- | -255,896.80 | -78,072.63 | -- | -37.56 | 0.00 | -- | -79.47 | 2.80 | 30.96 | -- | -26.59 | -- |
| Active Biotech AB publ | 0.00 | -54.17m | 242.37m | 11.00 | -- | 10.55 | -- | -- | -0.218 | -0.218 | 0.00 | 0.0868 | 0.00 | -- | -- | -- | -132.45 | -33.26 | -185.84 | -77.75 | -- | -- | -- | -600.70 | -- | -- | 0.1513 | -- | -- | -- | -17.15 | -- | -- | -- |
| Arctic Bioscience AS | 33.52m | -33.27m | 248.10m | -- | -- | 0.8485 | -- | 7.40 | -1.40 | -1.40 | 1.41 | 11.79 | 0.1024 | 0.7072 | 3.24 | -- | -10.17 | -- | -11.20 | -- | 33.98 | -- | -99.28 | -- | 4.03 | -- | 0.00 | -- | 59.29 | -- | 20.09 | -- | -- | -- |
Data as of Jun 01 2023. Currency figures normalised to Hamlet Pharma AB's reporting currency: Swedish Krona SEK
0.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Skandia Investment Management ABas of 30 Sep 2021 | 877.05k | 0.00% |
| Svenska Handelsbanken AB (Private Banking)as of 30 Sep 2021 | 290.65k | 0.00% |
Data from 31 Mar 2023 - 30 Apr 2023Source: FactSet Research Systems Inc.
